ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma

Drug Resistance Updates · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles